<DOC>
	<DOCNO>NCT00404235</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin ABI-007 , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study side effect well give carboplatin together ABI-007 work treat patient stage IV melanoma remove surgery .</brief_summary>
	<brief_title>Carboplatin ABI-007 Treating Patients With Stage IV Melanoma That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess safety antitumor activity carboplatin paclitaxel albumin-stabilized nanoparticle formulation ( ABI-007 ) patient unresectable stage IV melanoma receive prior chemotherapy metastatic disease . ( Cohort 1 ) - Assess safety antitumor activity regimen patient unresectable stage IV melanoma receive prior chemotherapy metastatic disease . ( Cohort 2 ) Secondary - Describe impact regimen parameter immune function angiogenesis patient . OUTLINE : This multicenter study . Patients stratify accord prior chemotherapy metastatic disease ( yes v ) . Patients receive paclitaxel albumin-stabilized nanoparticle formulation ( ABI-007 ) IV 30 minute follow carboplatin IV 30 minute day 1 , 8 , 15 . Treatment repeat every 28 day least 8 course absence disease progression unacceptable toxicity . Blood tumor tissue sample collect periodically evaluate secrete protein acidic rich cysteine ( SPARC ) content tumor tissue immunohistochemistry explore impact therapy immune homeostasis . Samples also analyze immunoenzyme technique angiogenesis marker . After completion study treatment , patient follow periodically 2 year . PROJECTED ACCRUAL : A total 74 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm unresectable stage IV melanoma Measurable disease Must formalinfixed , paraffinembedded tumor tissue available secrete protein acidic rich cysteine ( SPARC ) analysis pretreatment ( Mayo Clinic patient must willing submit repeat biopsy time tumor progression ) Brain metastasis allow provide previously treat progression ≥ 3 month Patients know brain metastasis may receive concurrent steroid treatment PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 3 month Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL ( may transfuse meet requirement ) Creatinine ≤ 1.5 time upper limit normal ( ULN ) Total bilirubin ≤ 1.5 time ULN ( elevate bilirubin allow patient document Gilbert 's syndrome ) AST ≤ 2.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month completion study therapy No uncontrolled intercurrent illness include , limited , follow : Active infection Congestive heart failure ( New York Heart Association class IIIIV heart disease ) No peripheral neuropathy ≥ grade 2 No malignancy within past 5 year except basal cell squamous cell carcinoma skin previously treat local resection carcinoma situ cervix PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy At least 4 week since prior radiotherapy At least 4 week since prior interferon interleukin2 At least 4 week since prior chemotherapy ( cohort 1 ) No prior chemotherapy metastatic setting ( cohort 2 ) No prior treatment melanoma follow agent : Platinum chemotherapy ( e.g. , carboplatin cisplatin ) Taxanes ( e.g. , paclitaxel docetaxel ) Paclitaxel albuminstabilized nanoparticle formulation ( ABI007 ) No concurrent chemotherapy No concurrent investigational agent No concurrent radiotherapy , include palliative radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>